Written and maintained by CASRAI Editorial Board
Published
On this page
A BSE/TSE statement is a supplier declaration about a product’s animal-origin materials and the basis for its transmissible spongiform encephalopathy assurance. Its value depends on the products, materials and processes it actually covers: a statement of processing compliance can differ substantially from an animal-free declaration.
Ask CASRAI · free to tryQuestion about this guide? Ask CASRAI answers with linked sources. 2 free questions a day, no account.
What it is and who runs it
BSE means bovine spongiform encephalopathy; TSE means transmissible spongiform encephalopathy. Suppliers use these terms in declarations accompanying laboratory products and manufacturing materials. There are separate roles to recognise: the supplier issuing the statement, the customer evaluating it and, where pharmaceutical certification is involved, the authority assessing the supporting dossier.
For example, Fisher Scientific publishes BSE/TSE statements identifying particular catalogue numbers. InVitria publishes a combined certificate-of-origin, animal-free and TSE/BSE statement describing its manufacturing inputs and product-contact materials. These are the respective suppliers’ attestations. Their titles alone do not establish that the documents have identical coverage.
The European Directorate for the Quality of Medicines and HealthCare, EDQM, operates a separate Certificate of Suitability procedure. Its TSE assessment concerns the relevant European Pharmacopoeia requirements. Keep the supplier document and the EDQM certification route distinct when organising a vendor qualification process: record who made each assertion before deciding what it demonstrates.
Eligibility: which materials and uses are in scope
For this compliance item, scope is more useful than an applicant eligibility list. Start with the material and its intended use. A laboratory buyer reviewing a supplier letter and a manufacturer assembling a medicinal-product dossier are answering different questions.
The Medicines Evaluation Board’s TSE requirements concern demonstrating material compliance during medicinal-product manufacture. That context matters: the page describes an EDQM suitability certificate or supporting scientific data as evidence of compliance. It does not establish a universal requirement for every research laboratory purchase to carry the same certificate.
For certification, EDQM’s assessment-scope FAQ specifies animal-derived materials submitted for certification that carry TSE transmission risk. It identifies European Pharmacopoeia monograph 1483, general chapter 5.2.8 and the dossier guidance PA/PH/CEP (06)2. A request for that certification therefore concerns an assessable material and its supporting dossier, rather than simply obtaining a supplier’s letter.
A practical scope check is to write down the product identifier, intended application and question the document must answer. “Does this declaration cover our catalogue item?” and “Does our medicinal-product dossier demonstrate compliance?” should remain separate review decisions.
EMA’s scope includes active substances, excipients, adjuvants and production materials or reagents derived from TSE-relevant species. Its examples include bovine serum albumin, enzymes and culture media. It also addresses materials contacting the medicinal product or manufacturing equipment where contamination is possible. Consequently, a review limited to the named ingredients in the finished product can miss a relevant manufacturing input. For a medicinal-product assessment, map the declaration to the actual material or contact point being evaluated.
What it requires
The useful content of a BSE/TSE statement is its stated basis and coverage. A reviewer should be able to identify the issuer, covered products, assertion made and evidence or manufacturing conditions on which it relies.
Three supplier examples show why precise wording matters. Fisher’s statement for catalogue 13131001, hinged cryo/freezer boxes, combines an animal-origin exclusion with an alternative reference to section 6.4 of EMA/410/01. Fisher’s statement for catalogue FB149563B, polystyrene test tubes with caps, bases compliance on processing of bovine-derived material under that section. InVitria describes animal-component-free coverage extending across raw materials, equipment and product-contact packaging. Each claim must retain its own scope and qualifications.
The downloadable data table below compares these declarations. It is a document comparison, not an independent certification of the products. A supplier’s assertion is recorded as an assertion; the table does not convert it into a laboratory test result.
For medicinal manufacture, EMA/410/01 rev.3 frames compliance through risk assessment. Its assessment considers animal origin, material and manufacturing controls; section 4 places final regulatory determination with the competent authority. A supplier declaration is evidence to evaluate within the relevant review.
Application or compliance steps
The following is a proposed document-review workflow, drawn from the differences in the official examples. It is not a regulator-prescribed form or an application for a universal BSE/TSE certificate.
- Identify the actual document. Save its issuer, title and product coverage. Match the catalogue number or stated product family to the item under review. Keep a general company assurance distinguishable from a product-specific declaration.
- Extract the assertion without strengthening it. Record whether it excludes animal inputs, describes processing conditions or gives another scoped assurance. Preserve alternatives and qualifications instead of compressing them into “animal-free”.
- Check what the coverage includes. Ask whether the declaration addresses the finished item alone or also inputs, processing and contact materials. InVitria’s explicit coverage illustrates why these boundaries deserve separate fields.
- Identify the evidence route. For an applicable medicinal-product review, distinguish a supplier statement, a TSE suitability certificate and scientific data supporting compliance. The Medicines Evaluation Board describes the latter two routes; they are not interchangeable labels for the supplier letter.
- Record the review outcome and open questions. State which question the document answers, which product it covers and what requires clarification. If the statement leaves its basis ambiguous, seek a product-specific explanation rather than supplying one yourself.
Read the document alongside the item’s other quality records. The certificate of analysis guide covers a different document-review task. A BSE/TSE declaration should be described according to its actual contents; do not silently relabel it as a batch analysis report.
Worked review of a BSE/TSE statement
Consider the published Fisher statement for FB149563B. A reviewer can match the catalogue number and recognise the named polystyrene tubes. The declaration then explains that compliance rests on processing bovine-derived material under section 6.4. The defensible review note is therefore “supplier declares processing-based compliance for the identified product”. “No animal-derived material is used” would add an assertion that this document does not make.
That distinction follows from the cited section itself: EMA section 6.4 addresses tallow derivatives and conditions for their compliance. Animal-origin exclusion and compliant processing answer different questions. If an internal material specification requires exclusion of animal-derived inputs, the next review action is clarification of that requirement against the supplier evidence, rather than treating the section reference as an exclusion.
A review record that preserves the evidence
An illustrative composite review record could use four fields: “item matched”, “supplier assertion”, “supporting document” and “review conclusion”. For the tube example, the item field would contain FB149563B; the assertion field would retain the processing basis; the document field would point to the Fisher statement; and the conclusion would identify the specific sourcing question it supports. This is an example of recording the evidence, not a completed qualification of a shipment.
If the requirement being checked is animal-component exclusion across processing and packaging, create separate coverage entries for those boundaries. The InVitria example supplies explicit assertions for them. An empty field for another supplier should remain an open question until that supplier provides evidence. This approach makes missing coverage visible while preserving the distinction between an affirmative supplier claim and the reviewer’s interpretation.
Typical timeline phases
Separate the local review sequence from an EDQM certification application. The supplier examples provide evidence to inspect; they do not establish a common turnaround time, recurring renewal date or expiry interval for every BSE/TSE statement.
For a local review, a practical sequence is document collection, product matching, interpretation, clarification and a recorded decision. These are suggested administrative phases. Their completion depends on resolving the actual question, not on a universal number of days.
For an EDQM application, the authority describes a defined progression: receipt and validation, assessment, questions where needed, resolution and issuance of the CEP. As described on the official page on 2026-11-15, the process can include exchanges with the applicant before a certificate is issued. Downloading a supplier declaration does not complete those phases.
EDQM’s electronic-submission instructions require prior CESP registration and electronic delivery to its Certification of Substances Department. TSE-risk submissions have a PDF exception to the usual eCTD format. These instructions concern a certification submission; they are not a direction for ordinary customers to submit each supplier letter to EDQM.
Common mistakes
- Turning alternative wording into a categorical claim. The cryo/freezer-box example combines different bases of assurance. A review summary should preserve that distinction or obtain clarification.
- Treating a document label as the delivered batch number. Both Fisher examples show “BSETSE” in the lot field. That label alone does not match a shipment’s production lot. Record what the field actually says before claiming batch-specific coverage.
- Assuming independent verification. Fisher explains that these certificates compile manufacturer-provided information which its channel has not independently verified. Retain that provenance in the qualification record.
- Rejecting an electronic document solely for lacking a handwritten signature. The Fisher examples explicitly state that they are valid without a signature. Apply the issuer’s stated validity condition and the applicable local document controls.
- Extending one supplier’s coverage to another. InVitria expressly addresses equipment and packaging. Those assertions do not establish the coverage of a different manufacturer’s declaration.
- Calling the letter regulatory approval. Separate the supplier assertion from the assessment and certification pathways described by the authorities.
For continuing reviews, retain the assertion and document version supporting the decision. Where a supplier changes a covered material or process, connect the evidence question to the organisation’s pharmaceutical change-control review. This is a suggested recordkeeping approach, not a supplier-specific promise of notification or a fixed renewal rule.
Related programs and documentation routes
The adjacent routes are supplier documentation, substance certification and a medicinal-product compliance dossier. Selecting the relevant one starts with the question being assessed. The table distinguishes their owners and the evidence each source describes.
| Route | Owner or reviewer | What the official source describes |
|---|---|---|
| Supplier BSE/TSE declaration | Issuing supplier; customer reviews its applicability | Product or manufacturing assurances with supplier-specific scope, illustrated by Fisher and InVitria. |
| EDQM TSE Certificate of Suitability | EDQM Certification of Substances Department | Assessment of submitted material against the relevant pharmacopoeial TSE criteria. EDQM identifies the required dossier guidance. |
| Medicinal-product TSE compliance evidence | Applicant and assessing competent authority | The Medicines Evaluation Board describes an EDQM suitability certificate or scientific data substantiating compliance. |
When an EDQM certificate is presented, its certification database allows checks of the substance, certificate type, full number and validity status. Match the record to the evidence being relied upon. A supplier letter mentioning EMA guidance and an EDQM database entry perform different evidentiary functions, even when both appear in the same qualification package.
Sources
- European Medicines Agency: EMA/410/01 rev.3, sections 1.2, 2, 3, 4 and 6.4. Checked 2026-11-15.
- Fisher Scientific: BSE/TSE statement for catalogue 13131001. Checked 2026-11-15.
- Fisher Scientific: BSE/TSE statement for catalogue FB149563B. Checked 2026-11-15.
- InVitria: Certificate of Origin and Animal-Free / TSE-BSE Statement. Checked 2026-11-15.
- EDQM: Which types of material require a TSE risk assessment? Checked 2026-11-15.
- EDQM: Submit a New Application. Checked 2026-11-15.
- EDQM: Submission format and electronic submission. Checked 2026-11-15.
- Medicines Evaluation Board: TSE requirements. Checked 2026-11-15.
Data: Scope and basis of three supplier BSE/TSE declarations
An original comparison of product scope, declared basis and provenance qualifiers in two Fisher Scientific declarations and an InVitria statement. These entries report supplier assertions, not independent product testing or certification.
| Supplier and document | Covered item or scope | Declared basis | Important qualifier | Source URL |
|---|---|---|---|---|
| Fisher Scientific 13131001 | Hinged cryo/freezer boxes | Animal-origin exclusion and/or EMA/410/01 section 6.4 compliance | Manufacturer-supplied data; not independently verified by Fisher | https://assets.fishersci.com/TFS-Assets/certificate/VGtQZk40eFRVYXVPSFpPcllxejdmZz09/CBT/CBT_13131001_BSETSE_1.pdf |
| Fisher Scientific FB149563B | Round-bottom polystyrene test tubes with cap | Bovine-derived material processed under EMA/410/01 section 6.4 | Final material suitability is the user responsibility; manufacturer data not independently verified by Fisher | https://assets.fishersci.com/TFS-Assets/certificate/SVBXWlZxVUVGS2RqWGtiN2t4d2ZtQT09/CBT/CBT_FB149563B_BSETSE_1.pdf |
| InVitria combined origin and TSE/BSE statement | Manufactured products; inputs, equipment and product-contact packaging | Supplier attests animal-component-free status to the tertiary level | Coverage is the supplier attestation for its own products | https://invitria.com/resources/certificate-of-origin-and-animal-free-tse-bse-statement/ |
Sources
- Fisher Scientific BSE/TSE Statement: catalogue 13131001 (accessed 2026-11-15)
- Fisher Scientific BSE/TSE Statement: catalogue FB149563B (accessed 2026-11-15)
- InVitria Certificate of Origin and Animal-Free / TSE-BSE Statement (accessed 2026-11-15)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







